Max Healthcare Institute Limited (NSE:MAXHEALTH)
India · Delayed Price · Currency is INR 1,153.40
+26.00 (2.31%)
Jul 3, 2026, 3:29 PM IST
Max Healthcare Institute Stock Forecast
Stock Price Forecast
According to 26 analysts polled by S&P Global, Max Healthcare Institute stock has a consensus rating of "Buy" and an average price target of ₹1,148. The average 1-year stock price forecast is 0.49% lower than the current stock price, while the lowest is ₹825.00 (-28.47%) and the highest is ₹1,300 (+12.71%).
Price Target: ₹1,148 (-0.49%)
Analyst Consensus: Buy
* Price targets were last updated on Feb 16, 2026.
Analyst Ratings
The average analyst rating for Max Healthcare Institute stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 11 | 11 | 12 | 13 | 12 | 12 |
| Buy | 8 | 7 | 7 | 7 | 7 | 7 |
| Hold | 4 | 3 | 2 | 2 | 3 | 3 |
| Sell | 2 | 3 | 3 | 3 | 3 | 3 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 26 | 25 | 25 | 26 | 26 | 26 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Geojit Research | Geojit Research | Buy Upgrades ₹1,280 → ₹1,180 | Buy | Upgrades | ₹1,280 → ₹1,180 | +2.31% | Feb 16, 2026 |
Unknown Analyst Prabhudas Lilladher No rating | Prabhudas Lilladher | Buy Maintains ₹1,300 | Buy | Maintains | ₹1,300 | +12.71% | Feb 10, 2026 |
Unknown Analyst Axis Direct No rating | Axis Direct | Buy Maintains ₹1,250 | Buy | Maintains | ₹1,250 | +8.38% | Feb 9, 2026 |
Financial Forecast
Revenue This Year
117.26B
from 83.73B
Increased by 40.04%
Revenue Next Year
139.33B
from 117.26B
Increased by 18.82%
EPS This Year
19.69
from 15.18
Increased by 29.65%
EPS Next Year
24.31
from 19.69
Increased by 23.51%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is INR.
Revenue Forecast
| Revenue | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | 130.5B | ||
| Avg | 117.3B | ||
| Low | 94.1B |
Revenue Growth
| Revenue Growth | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | 55.8% | ||
| Avg | 40.0% | ||
| Low | 12.3% |
EPS Forecast
| EPS | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | 22.89 | ||
| Avg | 19.69 | ||
| Low | 15.68 |
EPS Growth
| EPS Growth | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | 50.8% | ||
| Avg | 29.7% | ||
| Low | 3.3% |